Jarrett Jennifer 4

What Happened Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics (DMRA), was granted compensation awards on March 30, 2026: 500,000 restricted stock units (RSUs) and a derivative award representing the right to purchase 1,500,000 shares. Both grants were reported with an acquisition price of $0.00 (typical for equity awards); no shares were sold or purchased for cash in this filing.

Key Details

• Transaction date: March 30, 2026; Form 4 filed April 1, 2026 (appears timely — within typical two-business-day reporting window).
• Grants: 500,000 RSUs (non‑derivative) and a 1,500,000-share option/derivative award; both reported at $0.00.
• Vesting (per filing footnotes): RSUs vest 25% on each anniversary through the fourth anniversary of the grant date. The option vests 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030.
• Shares owned after the transaction: not specified in the information provided in this summary.
• Remarks: Reporting person is President and Chief Executive Officer. No 10b5-1, tax‑withholding sale, or late‑filing flag noted in the filing excerpt provided.

Context

• RSUs convert to actual shares only as they vest and are settled; the option award is a right to purchase shares subject to future vesting — neither represents immediately tradable shares upon grant.
• These awards are typical executive compensation and do not indicate an immediate buy or sell decision by the insider. They should be interpreted as future potential equity upside contingent on continued service and vesting conditions.